$HLVX
HilleVax, Inc.

2023 Q2 Form 10-Q Financial Statement

#000095017023021784 Filed on May 12, 2023

View on sec.gov

Income Statement

Concept 2023 Q2 2023 Q1
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $7.231M $5.795M
YoY Change 81.59% 122.63%
% of Gross Profit
Research & Development $22.95M $23.16M
YoY Change 160.06% 826.56%
% of Gross Profit
Depreciation & Amortization $100.0K $1.000K
YoY Change
% of Gross Profit
Operating Expenses $30.18M $28.96M
YoY Change 135.67% 155.96%
Operating Profit -$30.18M -$28.96M
YoY Change 135.67% 155.96%
Interest Expense $500.0K $449.0K
YoY Change -43.69% -78.25%
% of Operating Profit
Other Income/Expense, Net $2.282M $2.070M
YoY Change -105.55% -103.66%
Pretax Income -$27.90M -$26.89M
YoY Change -48.26% -60.39%
Income Tax
% Of Pretax Income
Net Earnings -$27.90M -$26.89M
YoY Change -48.26% -60.39%
Net Earnings / Revenue
Basic Earnings Per Share -$0.74 -$0.71
Diluted Earnings Per Share -$0.74 -$0.71
COMMON SHARES
Basic Shares Outstanding 39.20M 39.25M
Diluted Shares Outstanding 37.95M 37.75M

Balance Sheet

Concept 2023 Q2 2023 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $244.1M $260.5M
YoY Change -22.43% 134.19%
Cash & Equivalents $158.4M $260.5M
Short-Term Investments $85.68M
Other Short-Term Assets $8.989M $9.317M
YoY Change 83.71% 1841.04%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $253.0M $269.9M
YoY Change -20.8% 141.52%
LONG-TERM ASSETS
Property, Plant & Equipment $13.14M $10.45M
YoY Change -34.53% 5837.5%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $23.00K $22.00K
YoY Change 9.52% -99.21%
Total Long-Term Assets $33.48M $31.10M
YoY Change 54.11% 949.33%
TOTAL ASSETS
Total Short-Term Assets $253.0M $269.9M
Total Long-Term Assets $33.48M $31.10M
Total Assets $286.5M $301.0M
YoY Change -16.03% 162.4%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $151.0K $1.744M
YoY Change -97.5% -56.51%
Accrued Expenses $17.65M $17.41M
YoY Change 174.93% 264.42%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change -100.0%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $18.34M $19.27M
YoY Change 46.59% -93.19%
LONG-TERM LIABILITIES
Long-Term Debt $24.84M $14.90M
YoY Change 428.74%
Other Long-Term Liabilities $922.0K $747.0K
YoY Change 1038.27% 74600.0%
Total Long-Term Liabilities $25.76M $15.65M
YoY Change 439.07% 1564900.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $18.34M $19.27M
Total Long-Term Liabilities $25.76M $15.65M
Total Liabilities $67.76M $57.90M
YoY Change 77.95% -79.55%
SHAREHOLDERS EQUITY
Retained Earnings -$319.8M -$291.9M
YoY Change 40.87% 68.65%
Common Stock $538.9M $535.2M
YoY Change 1.64% 11290.19%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $218.8M $243.1M
YoY Change
Total Liabilities & Shareholders Equity $286.5M $301.0M
YoY Change -16.03% 162.4%

Cashflow Statement

Concept 2023 Q2 2023 Q1
OPERATING ACTIVITIES
Net Income -$27.90M -$26.89M
YoY Change -48.26% -60.39%
Depreciation, Depletion And Amortization $100.0K $1.000K
YoY Change
Cash From Operating Activities -$22.42M -$15.95M
YoY Change 69.7% 48.89%
INVESTING ACTIVITIES
Capital Expenditures $4.839M $2.985M
YoY Change
Acquisitions
YoY Change
Other Investing Activities -$85.11M $0.00
YoY Change -100.0%
Cash From Investing Activities -$89.95M -$2.985M
YoY Change 19.4%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 10.20M 80.00K
YoY Change -95.33% -180.81%
NET CHANGE
Cash From Operating Activities -22.42M -15.95M
Cash From Investing Activities -89.95M -2.985M
Cash From Financing Activities 10.20M 80.00K
Net Change In Cash -102.2M -18.86M
YoY Change -149.84% 41.65%
FREE CASH FLOW
Cash From Operating Activities -$22.42M -$15.95M
Capital Expenditures $4.839M $2.985M
Free Cash Flow -$27.26M -$18.94M
YoY Change 106.33%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001888012
CY2023Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q1 us-gaap Preferred Stock Value
PreferredStockValue
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2023Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2023Q1 dei Amendment Flag
AmendmentFlag
false
CY2023Q1 dei Document Type
DocumentType
10-Q
CY2023Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2023Q1 dei Document Period End Date
DocumentPeriodEndDate
2023-03-31
CY2023Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2023Q1 dei Entity File Number
EntityFileNumber
001-41365
CY2023Q1 dei Entity Registrant Name
EntityRegistrantName
HILLEVAX, INC.
CY2023Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2023Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
85-0545060
CY2023Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
75 State Street
CY2023Q1 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 100 - #9995
CY2023Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Boston
CY2023Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
CY2023Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02109
CY2023Q1 dei City Area Code
CityAreaCode
617
CY2023Q1 dei Local Phone Number
LocalPhoneNumber
213-5054
CY2023Q1 dei Security12b Title
Security12bTitle
Common Stock, $0.0001 par value per share
CY2023Q1 dei Trading Symbol
TradingSymbol
HLVX
CY2023Q1 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2023Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2023Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2023Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2023Q1 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2023Q1 dei Entity Shell Company
EntityShellCompany
false
CY2023Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
39200174
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
260542000
CY2023Q1 us-gaap Assets Current
AssetsCurrent
269859000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
279401000
CY2023Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
9317000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
11212000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
290613000
CY2023Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
10450000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
5586000
CY2023Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
18999000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
19359000
CY2023Q1 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
1631000
CY2022Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
1631000
CY2023Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
22000
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
22000
CY2023Q1 us-gaap Assets
Assets
300961000
CY2022Q4 us-gaap Assets
Assets
317211000
CY2023Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
1744000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
4744000
CY2023Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
17412000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
8210000
CY2023Q1 us-gaap Interest And Dividends Payable Current
InterestAndDividendsPayableCurrent
79000
CY2022Q4 us-gaap Interest And Dividends Payable Current
InterestAndDividendsPayableCurrent
55000
CY2023Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
38000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
37000
CY2023Q1 us-gaap Liabilities Current
LiabilitiesCurrent
19273000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
13046000
CY2023Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
22977000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
21569000
CY2023Q1 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
14903000
CY2022Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
14792000
CY2023Q1 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
747000
CY2022Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
575000
CY2023Q1 us-gaap Liabilities
Liabilities
57900000
CY2022Q4 us-gaap Liabilities
Liabilities
49982000
CY2023Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
50000000
CY2023Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
50000000
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2023Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2023Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
39200174
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
39240746
CY2023Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
37841987
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
37656037
CY2023Q1 us-gaap Common Stock Value
CommonStockValue
4000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
4000
CY2023Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
535221000
CY2022Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
532499000
CY2023Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-282000
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-281000
CY2023Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-291882000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-264993000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
243061000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
267229000
CY2023Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
300961000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
317211000
CY2023Q1 us-gaap Related Party Costs
RelatedPartyCosts
168000
CY2022Q1 us-gaap Related Party Costs
RelatedPartyCosts
1422000
CY2023Q1 hlvx Research And Development Expense Excluding In Progress Research And Development
ResearchAndDevelopmentExpenseExcludingInProgressResearchAndDevelopment
23164000
CY2022Q1 hlvx Research And Development Expense Excluding In Progress Research And Development
ResearchAndDevelopmentExpenseExcludingInProgressResearchAndDevelopment
6211000
CY2022Q1 hlvx Research And Development In Process With Related Party
ResearchAndDevelopmentInProcessWithRelatedParty
2500000
CY2023Q1 us-gaap Related Party Transaction Selling General And Administrative Expenses From Transactions With Related Party
RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty
3000
CY2022Q1 us-gaap Related Party Transaction Selling General And Administrative Expenses From Transactions With Related Party
RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty
26000
CY2023Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5795000
CY2022Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2603000
CY2023Q1 us-gaap Operating Expenses
OperatingExpenses
28959000
CY2022Q1 us-gaap Operating Expenses
OperatingExpenses
11314000
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-28959000
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-11314000
CY2023Q1 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
2574000
CY2022Q1 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
6000
CY2023Q1 us-gaap Interest Expense Related Party
InterestExpenseRelatedParty
0
CY2022Q1 us-gaap Interest Expense Related Party
InterestExpenseRelatedParty
529000
CY2023Q1 us-gaap Interest Expense
InterestExpense
449000
CY2022Q1 us-gaap Interest Expense
InterestExpense
2064000
CY2023Q1 hlvx Change In Fair Value Of Convertible Promissory Notes Related Party
ChangeInFairValueOfConvertiblePromissoryNotesRelatedParty
0
CY2022Q1 hlvx Change In Fair Value Of Convertible Promissory Notes Related Party
ChangeInFairValueOfConvertiblePromissoryNotesRelatedParty
4378000
CY2022Q1 hlvx Change In Fair Value Of Convertible Promissory Notes
ChangeInFairValueOfConvertiblePromissoryNotes
17073000
CY2022Q1 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
37424000
CY2023Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-55000
CY2022Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-18000
CY2023Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
2070000
CY2022Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-56573000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-26889000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-67887000
CY2023Q1 us-gaap Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Plan Amendments Tax Effect
OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansPlanAmendmentsTaxEffect
-1000
CY2023Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-26890000
CY2022Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-67887000
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.71
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.71
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-10.06
CY2022Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-10.06
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
37753522
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
37753522
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
6748668
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
6748668
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
-100757000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
272000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-67887000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
-168372000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
267229000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2642000
CY2023Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
80000
CY2023Q1 us-gaap Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Net Of Tax
OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax
-1000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-26889000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
243061000
CY2023Q1 us-gaap Profit Loss
ProfitLoss
-26889000
CY2022Q1 us-gaap Profit Loss
ProfitLoss
-67887000
CY2023Q1 us-gaap Depreciation
Depreciation
1000
CY2023Q1 us-gaap Share Based Compensation
ShareBasedCompensation
2642000
CY2022Q1 us-gaap Share Based Compensation
ShareBasedCompensation
272000
CY2023Q1 hlvx Change In Fair Value Of Convertible Promissory Notes Related Party
ChangeInFairValueOfConvertiblePromissoryNotesRelatedParty
0
CY2022Q1 hlvx Change In Fair Value Of Convertible Promissory Notes Related Party
ChangeInFairValueOfConvertiblePromissoryNotesRelatedParty
4378000
CY2022Q1 hlvx Change In Fair Value Of Convertible Promissory Notes
ChangeInFairValueOfConvertiblePromissoryNotes
17073000
CY2022Q1 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
37424000
CY2023Q1 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
360000
CY2022Q1 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
13000
CY2023Q1 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
126000
CY2023Q1 us-gaap Paid In Kind Interest
PaidInKindInterest
94000
CY2022Q1 hlvx Research And Development In Process With Related Party
ResearchAndDevelopmentInProcessWithRelatedParty
2500000
CY2022Q1 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-42000
CY2023Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-1895000
CY2022Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
339000
CY2023Q1 hlvx Increase Decrease In Accounts Payable Accrued Expenses And Other Long Term Liabilities Related Parties
IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLongTermLiabilitiesRelatedParties
31000
CY2022Q1 hlvx Increase Decrease In Accounts Payable Accrued Expenses And Other Long Term Liabilities Related Parties
IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLongTermLiabilitiesRelatedParties
-3402000
CY2023Q1 hlvx Increase Decrease In Accounts Payable Accrued Liabilities And Other Long Term Liabilities
IncreaseDecreaseInAccountsPayableAccruedLiabilitiesAndOtherLongTermLiabilities
4384000
CY2022Q1 hlvx Increase Decrease In Accounts Payable Accrued Liabilities And Other Long Term Liabilities
IncreaseDecreaseInAccountsPayableAccruedLiabilitiesAndOtherLongTermLiabilities
-1868000
CY2023Q1 hlvx Increase Decrease In Interest Payable Related Parties
IncreaseDecreaseInInterestPayableRelatedParties
0
CY2022Q1 hlvx Increase Decrease In Interest Payable Related Parties
IncreaseDecreaseInInterestPayableRelatedParties
529000
CY2023Q1 us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
24000
CY2022Q1 us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
2064000
CY2023Q1 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
1409000
CY2022Q1 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-9000
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-15954000
CY2022Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-10715000
CY2022Q1 us-gaap Payments To Acquire In Process Research And Development
PaymentsToAcquireInProcessResearchAndDevelopment
2500000
CY2023Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2985000
CY2023Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-2985000
CY2022Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-2500000
CY2022Q1 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
99000
CY2023Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
80000
CY2023Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
80000
CY2022Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-99000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-18859000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-13314000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
281032000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
124566000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
262173000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
111252000
CY2023Q1 us-gaap Interest Paid Net
InterestPaidNet
192000
CY2022Q1 hlvx Unpaid Initial Public Offering Costs
UnpaidInitialPublicOfferingCosts
548000
CY2023Q1 hlvx Unpaid Property And Equipment Purchases
UnpaidPropertyAndEquipmentPurchases
3453000
CY2023Q1 hlvx Accreted Final Interest Payment Fees
AccretedFinalInterestPaymentFees
109000
CY2022Q2 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
1.681
CY2022Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000
CY2022Q2 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
13529750
CY2022Q2 us-gaap Sale Of Stock Price Per Share
SaleOfStockPricePerShare
17.00
CY2022Q2 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
209500000
CY2022Q2 hlvx Underwriting Discounts Commissions And Offering Costs
UnderwritingDiscountsCommissionsAndOfferingCosts
20500000
CY2023Q1 us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:16.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Use of Estimates</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The preparation of the Company’s unaudited condensed consolidated financial statements requires it to make estimates and assumptions that impact the reported amounts of assets, liabilities and expenses and the disclosure of contingent assets and liabilities in the Company’s condensed consolidated financial statements and accompanying notes. The most significant estimates in the Company’s unaudited condensed consolidated financial statements relate to accruals for research and development expenses, and the valuation of convertible promissory notes, warrant liabilities and various other equity instruments. Although these estimates are based on the Company’s knowledge of current events and actions it may undertake in the future, actual results could differ materially from those estimates and assumptions.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
CY2022Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
9401519
CY2023Q1 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Concentrations of Credit Risk</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash, cash equivalents and restricted cash. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts and management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held.</span></p>
CY2023Q1 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2023Q1 hlvx Weighted Average Unvested Shares Excluded From Computation Of Earnings Per Share Amount
WeightedAverageUnvestedSharesExcludedFromComputationOfEarningsPerShareAmount
1492789
CY2022Q1 hlvx Weighted Average Unvested Shares Excluded From Computation Of Earnings Per Share Amount
WeightedAverageUnvestedSharesExcludedFromComputationOfEarningsPerShareAmount
2476653
CY2023Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5510787
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
4018000
CY2023Q1 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
10451000
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
5587000
CY2023Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1000
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1000
CY2023Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
10450000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
5586000
CY2023Q1 hlvx Accrued Research And Development Expenses
AccruedResearchAndDevelopmentExpenses
11638000
CY2022Q4 hlvx Accrued Research And Development Expenses
AccruedResearchAndDevelopmentExpenses
3510000
CY2023Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1657000
CY2023Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
4117000
CY2023Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
871000
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
682000
CY2023Q1 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
17412000
CY2022Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
8210000
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
260542000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
279401000
CY2023Q1 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
1631000
CY2022Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
1631000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
262173000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
281032000
CY2023Q1 us-gaap Operating Lease Expense
OperatingLeaseExpense
779000
CY2022Q1 us-gaap Operating Lease Expense
OperatingLeaseExpense
0
CY2023Q1 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P9Y8M12D
CY2022Q1 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P4Y6M
CY2023Q1 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.074
CY2022Q1 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.060
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
2613000
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
3584000
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
3688000
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
3784000
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
3860000
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
21075000
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
38604000
CY2023Q1 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
11113000
CY2023Q1 hlvx Lessee Operating Lease Tenant Improvement Reimbursements
LesseeOperatingLeaseTenantImprovementReimbursements
4476000
CY2023Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
23015000
CY2023Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
38000
CY2023Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
22977000
CY2023Q1 us-gaap Description Of Defined Contribution Pension And Other Postretirement Plans
DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans
the Company made matching contributions equal to 100% of the employee’s contributions, subject to a maximum of 4% of eligible compensation. The Company made matching contributions of $0.2 million during the three months ended March 31, 2023. The Company did not make any matching contributions during the three months ended March 31, 2022.
CY2022Q4 us-gaap Defined Contribution Plan Employer Matching Contribution Percent Of Match
DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
1
CY2022Q4 hlvx Defined Contribution Plan Maximum Eligible Compensation
DefinedContributionPlanMaximumEligibleCompensation
0.04
CY2023Q1 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
200000
CY2022Q1 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
0
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.943
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.881
CY2023Q1 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
15000000
CY2023Q1 hlvx Accumulated Paid In Kind Interest Amount
AccumulatedPaidInKindInterestAmount
181000
CY2023Q1 hlvx Debt Instrument Carrying Amount Including Paid In Kind Interest
DebtInstrumentCarryingAmountIncludingPaidInKindInterest
15181000
CY2023Q1 us-gaap Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net
DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
278000
CY2023Q1 us-gaap Long Term Debt
LongTermDebt
14903000
CY2023Q1 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
709000
CY2023Q1 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
967000
CY2023Q1 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
5063000
CY2023Q1 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Four
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
7982000
CY2023Q1 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Five
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive
7405000
CY2023Q1 hlvx Principal Payments Interest Payments And Final Payment Fee
PrincipalPaymentsInterestPaymentsAndFinalPaymentFee
22126000
CY2023Q1 hlvx Debt Instrument Interest And Final Payment Fee
DebtInstrumentInterestAndFinalPaymentFee
6945000
CY2023Q1 hlvx Long Term Debt Net Of Interest Pik Interest And Back End Fee
LongTermDebtNetOfInterestPikInterestAndBackEndFee
15181000
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.019
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.042
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.019
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.025
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.834
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.895
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2023Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2642000
CY2022Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
272000
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
13.80
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
5.92
CY2023Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
29400000
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
1584709
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
759266
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
51954
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
174568
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
2117453
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
0
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
18.00
CY2023Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Share Based Awards Other Than Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
13100000
CY2023Q1 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
8282245

Files In Submission

Name View Source Status
hlvx-20230331_def.xml Edgar Link unprocessable
0000950170-23-021784-index-headers.html Edgar Link pending
0000950170-23-021784-index.html Edgar Link pending
0000950170-23-021784.txt Edgar Link pending
0000950170-23-021784-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
hlvx-20230331.htm Edgar Link pending
hlvx-20230331.xsd Edgar Link pending
hlvx-ex31_1.htm Edgar Link pending
hlvx-ex31_2.htm Edgar Link pending
hlvx-ex32_1.htm Edgar Link pending
hlvx-ex32_2.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
hlvx-20230331_cal.xml Edgar Link unprocessable
hlvx-20230331_pre.xml Edgar Link unprocessable
hlvx-20230331_lab.xml Edgar Link unprocessable
hlvx-20230331_htm.xml Edgar Link completed
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending